We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
INGN Stock Gains Post Latest Launch to Expand Respiratory Care Suite
Read MoreHide Full Article
Key Takeaways
Inogen launched FDA-cleared Aurora CPAP masks for OSA treatment in the U.S. market.
Inogen designed the Aurora line to fit diverse facial structures and support consistent CPAP therapy use.
INGN aims to grow its home respiratory portfolio and enter sleep therapy using existing distribution channels.
Inogen, Inc. (INGN - Free Report) has launched Aurora CPAP (continuous positive airway pressure) masks for Obstructive Sleep Apnea (OSA) in the United States yesterday. The FDA 510(k)-cleared mask is a new product within the company’s expanding portfolio.
Per INGN, the Aurora Mask portfolio — which includes the F1 Full Face, N1 Nasal Cushion and P1 Nasal Pillows — has been specifically designed to meet the diverse needs of most patients using CPAP devices. Aurora Masks provide options for different facial structures and therapy needs, promoting patient-focused care and encouraging consistent use in sleep and respiratory therapy.
The latest offering is expected to significantly boost Inogen’s respiratory care portfolio and strengthen its foothold in the OSA space.
Trend in INGN Stock Following the News
Following the announcement, shares of the company gained nearly 7.8% till yesterday’s close.
Historically, the company has gained a top-line boost from its various product innovations and launches. We expect market sentiment for the stock to remain positive around this announcement, too.
Inogen currently has a market capitalization of $198.7 million. It has a price-to-sales ratio (P/S) of 0.6 compared with the industry’s 3.9. In the last reported quarter, INGN delivered an earnings surprise of 9.1%.
Significance of Inogen’s Latest Offering
Per Inogen, Aurora Masks are expected to establish the company’s presence in the growing sleep-therapy market and expand its addressable market opportunity. The company intends to leverage its existing distribution channels and partnerships to bring Aurora CPAP masks to customers and strengthen relationships with providers.
Management believes that the launch of Aurora CPAP masks is a pivotal step for Inogen toward expanding into a broad home care respiratory solutions company and its entry into the sleep apnea market.
Industry Prospects in Favor of INGN
Per a report by Grand View Research, the global sleep apnea devices market was estimated at $4.5 billion in 2023 and is anticipated to reach $6.9 billion by 2030 at a CAGR of 6.2%. Factors like technological advancements and the growing elderly population's vulnerability to sleep apnea are likely to drive the market.
Given the market potential, the latest launch is expected to provide a significant boost to Inogen’s business.
Inogen’s Notable Launches
In November 2025, Inogen announced third-quarter 2025 results, wherein it confirmed that it initiated a limited market release of the Simeox airway clearance device in the United States.
In June, Inogen announced the launch of Voxi 5, a new stationary oxygen concentrator designed to enhance access to high-quality oxygen therapy for long-term care patients in the United States.
INGN’s Share Price Performance
Shares of the company have lost 24.6% in the past year against the industry’s 4.4% rise and the S&P 500’s gain of 19.3%.
Image Source: Zacks Investment Research
Inogen’s Zacks Rank & Key Picks
Currently, INGN carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Boston Scientific Corporation (BSX - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) .
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 16.4%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have gained 2.8% against the industry’s 3.2% decline in the past year.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.9%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 9.4%.
Cardinal Health has rallied 69.1% compared with the industry’s 11.1% growth in the past year.
IDEXX, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.1%.
IDEXX’s shares have gained 65.3% compared with the industry’s 4.4% growth in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
INGN Stock Gains Post Latest Launch to Expand Respiratory Care Suite
Key Takeaways
Inogen, Inc. (INGN - Free Report) has launched Aurora CPAP (continuous positive airway pressure) masks for Obstructive Sleep Apnea (OSA) in the United States yesterday. The FDA 510(k)-cleared mask is a new product within the company’s expanding portfolio.
Per INGN, the Aurora Mask portfolio — which includes the F1 Full Face, N1 Nasal Cushion and P1 Nasal Pillows — has been specifically designed to meet the diverse needs of most patients using CPAP devices. Aurora Masks provide options for different facial structures and therapy needs, promoting patient-focused care and encouraging consistent use in sleep and respiratory therapy.
The latest offering is expected to significantly boost Inogen’s respiratory care portfolio and strengthen its foothold in the OSA space.
Trend in INGN Stock Following the News
Following the announcement, shares of the company gained nearly 7.8% till yesterday’s close.
Historically, the company has gained a top-line boost from its various product innovations and launches. We expect market sentiment for the stock to remain positive around this announcement, too.
Inogen currently has a market capitalization of $198.7 million. It has a price-to-sales ratio (P/S) of 0.6 compared with the industry’s 3.9. In the last reported quarter, INGN delivered an earnings surprise of 9.1%.
Significance of Inogen’s Latest Offering
Per Inogen, Aurora Masks are expected to establish the company’s presence in the growing sleep-therapy market and expand its addressable market opportunity. The company intends to leverage its existing distribution channels and partnerships to bring Aurora CPAP masks to customers and strengthen relationships with providers.
Management believes that the launch of Aurora CPAP masks is a pivotal step for Inogen toward expanding into a broad home care respiratory solutions company and its entry into the sleep apnea market.
Industry Prospects in Favor of INGN
Per a report by Grand View Research, the global sleep apnea devices market was estimated at $4.5 billion in 2023 and is anticipated to reach $6.9 billion by 2030 at a CAGR of 6.2%. Factors like technological advancements and the growing elderly population's vulnerability to sleep apnea are likely to drive the market.
Given the market potential, the latest launch is expected to provide a significant boost to Inogen’s business.
Inogen’s Notable Launches
In November 2025, Inogen announced third-quarter 2025 results, wherein it confirmed that it initiated a limited market release of the Simeox airway clearance device in the United States.
In June, Inogen announced the launch of Voxi 5, a new stationary oxygen concentrator designed to enhance access to high-quality oxygen therapy for long-term care patients in the United States.
INGN’s Share Price Performance
Shares of the company have lost 24.6% in the past year against the industry’s 4.4% rise and the S&P 500’s gain of 19.3%.
Image Source: Zacks Investment Research
Inogen’s Zacks Rank & Key Picks
Currently, INGN carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Boston Scientific Corporation (BSX - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) .
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 16.4%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have gained 2.8% against the industry’s 3.2% decline in the past year.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.9%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 9.4%.
Cardinal Health has rallied 69.1% compared with the industry’s 11.1% growth in the past year.
IDEXX, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.1%.
IDEXX’s shares have gained 65.3% compared with the industry’s 4.4% growth in the past year.